| Patents for C12Q 1 - Measuring or testing processes involving enzymes or micro-organisms; Compositions therefor; Processes of preparing such compositions (300,231) |
|---|
| 04/28/2011 | US20110097723 Methods and reagents for analyte detection |
| 04/28/2011 | US20110097722 Cold Shock Protein Compositions and Methods and Kits for the Use Thereof |
| 04/28/2011 | US20110097721 In vivo gene sensors |
| 04/28/2011 | US20110097720 Screening method for selected amino lipid-containing compositions |
| 04/28/2011 | US20110097719 Neprilysin Gene Polymorphism and Amyloid Beta Plaques in Traumatic Brain Injury |
| 04/28/2011 | US20110097718 Ms-compatible nonionic or zwitterionic surfactants in free-flow electrophoresis |
| 04/28/2011 | US20110097717 Gene Expression Profiling For Identification of Cancer |
| 04/28/2011 | US20110097716 Methods for Detecting Oligonucleotides |
| 04/28/2011 | US20110097715 Method for purifying or detecting a target protein |
| 04/28/2011 | US20110097714 Amplification method of methylated or unmethylated nucleic acid |
| 04/28/2011 | US20110097713 Compositions and methods for pharmacogenomic screening of CYP2C9 and VKORC1 |
| 04/28/2011 | US20110097712 Method for detecting and quantifying rare mutations/polymorphisms |
| 04/28/2011 | US20110097711 Method of judging inflammatory disease by using single nucleotdie polymorphism |
| 04/28/2011 | US20110097710 Methods for detecting atrial fibrillation and related conditions |
| 04/28/2011 | US20110097709 Method for modifying a nucleic acid |
| 04/28/2011 | US20110097708 Assessment of human papilloma virus-related disease |
| 04/28/2011 | US20110097707 RNAi Agents Comprising Universal Nucleobases |
| 04/28/2011 | US20110097706 Micro-reactor for observing particles in a fluid |
| 04/28/2011 | US20110097705 Surface-assisted hemagglutination and hemagglutination inhibition assays |
| 04/28/2011 | US20110097704 Compositions for use in identification of picornaviruses |
| 04/28/2011 | US20110097703 Method for carrying out a qualitative preliminary instant diagnosis of oncologic diseases |
| 04/28/2011 | US20110097702 Methods and compositions for in situ detection of microorganisms on a surface |
| 04/28/2011 | US20110097423 Gene Prognosis Predictor Signature for Colorectal Carcinoma |
| 04/28/2011 | US20110097389 P53 biomarkers |
| 04/28/2011 | US20110097353 Poultry viral materials and methods related thereto |
| 04/28/2011 | US20110097352 Inducing cellular immune responses to hepatitis B virus using peptide and nucleic acid compositions |
| 04/28/2011 | US20110097335 Abc transporter protein expression inhibitor |
| 04/28/2011 | US20110097333 Therapeutic and diagnostic agents |
| 04/28/2011 | US20110097330 Novel Gene Disruptions, Compostitions and Methods Relating Thereto |
| 04/28/2011 | US20110097329 Compositions and methods for treating cancer and modulating stress granule formation |
| 04/28/2011 | US20110097325 Modulation of T cell Differentiation for the treatment of T helper cell mediated diseases |
| 04/28/2011 | US20110097317 Thioredoxin Interacting Protein (TXNIP) As Regulator Of Vascular Function |
| 04/28/2011 | US20110097271 Colon Cancer Associated Transcript 1 (CCAT1) As A Cancer Marker |
| 04/28/2011 | US20110097270 Monoclonal Antibodies That Bind or Neutralize Hepatitis B Virus |
| 04/28/2011 | DE202004021824U1 Mikroprozessoren und Vorrichtungen zur Überwachung von physiologischen Analyten Microprocessors and devices for monitoring physiological analytes |
| 04/28/2011 | DE102009045924A1 Analysis of influence of substances on nerve fibers of projection systems comprises culturing e.g. first tissue sample isolated from first region of CNS of animal, adding substance to be examined, determining and analysis of fiber property |
| 04/28/2011 | CA2793835A1 Methods and compositions for cell-proliferation-related disorders |
| 04/28/2011 | CA2779234A1 Toxicity-associated genes, genetic variants, and use thereof |
| 04/28/2011 | CA2778613A1 Methods and compositions for panic disorders |
| 04/28/2011 | CA2778497A1 Cell free cd4 quantitation and methods of use |
| 04/28/2011 | CA2778478A1 Detection and treatment of lrp4-associated neurotransmission disorders |
| 04/28/2011 | CA2778449A1 Amplification primers with non-standard bases for increased reaction specificity |
| 04/28/2011 | CA2778442A1 Methods and compositions for modulating hepsin activation of macrophage-stimulating protein |
| 04/28/2011 | CA2778338A1 Methods and related devices for single molecule whole genome analysis |
| 04/28/2011 | CA2777928A1 Genetic polymorphisms in age-related macular degeneration |
| 04/28/2011 | CA2777421A1 Detection of plurality of targets in biological samples |
| 04/28/2011 | CA2775273A1 Composition, method and kit for detecting bacteria by means of sequencing |
| 04/28/2011 | CA2769825A1 Genetic fingerprinting and identification method |
| 04/27/2011 | EP2315033A2 Compositions and methods for treating skin disorders |
| 04/27/2011 | EP2315012A2 Sensor cartridge and measuring device |
| 04/27/2011 | EP2315005A2 Apparatus and method for fluorescent detection in biological samples |
| 04/27/2011 | EP2315002A2 Filter module for an optical instrument used in particular for monitoring DNA polymerase chain reactions |
| 04/27/2011 | EP2314721A1 Porcine reproductive and respiratory syndrome isolates and methods of use |
| 04/27/2011 | EP2314720A1 Detection of respiratory viruses |
| 04/27/2011 | EP2314717A1 Polynucleotide primers for the detection of mutations in EGFR |
| 04/27/2011 | EP2314716A1 Compositions, kits, and methods for identification, assessment, prevention, and therapy of cervical cancer |
| 04/27/2011 | EP2314715A2 Method for the amplification of hla class i alleles |
| 04/27/2011 | EP2314714A1 Disease susceptibility |
| 04/27/2011 | EP2314713A1 Oligonucleotide probe, and use thereof |
| 04/27/2011 | EP2314712A1 Expression vectors encoding epitopes of antigens and methods for their design |
| 04/27/2011 | EP2314704A1 Tomato fruit having increased firmness |
| 04/27/2011 | EP2314697A1 Streptococcus pneumoniae proteins and nucleic acids |
| 04/27/2011 | EP2314696A1 Therapeutic uses of human Interleukin-B50 antagonist. |
| 04/27/2011 | EP2314695A2 Ligand for receptor activator of NF-kappa B, ligand is member of TNF superfamily |
| 04/27/2011 | EP2314692A2 Methods and compositions for enhancing the efficacy and specificity of RNAi |
| 04/27/2011 | EP2314691A2 Fuctional and hyperfunctional siRNA |
| 04/27/2011 | EP2314690A1 RNA-interference by single-stranded RNA molecules |
| 04/27/2011 | EP2314688A1 Methods and compositions involving miRNA and miRNA inhibitor molecules |
| 04/27/2011 | EP2314684A1 Fluorescent protein and chromoprotein |
| 04/27/2011 | EP2314683A1 Fluorescent protein and chromoprotein |
| 04/27/2011 | EP2314682A2 Fluorescent protein |
| 04/27/2011 | EP2314680A1 Method for amplification of target nucleic acid sequence, method for detection of mutation by using the method, and reagents for use in the methods |
| 04/27/2011 | EP2314678A1 Micro-rna associated with rheumatoid arthritis |
| 04/27/2011 | EP2314677A1 Method for collection of nucleic acid from fecal sample, method for analysis of nucleic acid, and apparatus for treatment of fecal sample |
| 04/27/2011 | EP2314676A1 Compositions and methods for the treatment of immune related diseases |
| 04/27/2011 | EP2314675A2 Mutation in OAS1 genes |
| 04/27/2011 | EP2314632A2 Oligosaccharidic compounds derived from heparin |
| 04/27/2011 | EP2314631A2 Method for detection and quantification of glycoserine in a sample of heparin or heparin products |
| 04/27/2011 | EP2314613A2 Genetic products which are differentially expressed in tumours and use thereof |
| 04/27/2011 | EP2314612A2 Differential in tumour gene products and use of same |
| 04/27/2011 | EP2314611A2 Differential in tumour gene products and use of same |
| 04/27/2011 | EP2314610A2 Differential in tumour gene products and use of same |
| 04/27/2011 | EP2314601A1 Anti-inflammatory compounds and uses thereof |
| 04/27/2011 | EP2314596A2 DNA-Polymerase blends and mutant DNA polymerases |
| 04/27/2011 | EP2314595A2 Oligonucleotide compositions and methods for treating disease including inflammatory conditions |
| 04/27/2011 | EP2314314A2 Chlamydia trachomatis antigens for vaccine and diagnostic use |
| 04/27/2011 | EP2314306A1 Biological pacemaker |
| 04/27/2011 | EP2313850A2 Automatic information transfer by color encoded fields |
| 04/27/2011 | EP2313781A1 Methods and kit for analyte detection |
| 04/27/2011 | EP2313779A2 Use of defensin alpha 1 and/or defensin alpha 4, as a marker for predicting treatment response and/or a relapse in a patient suffering from chronic myeloid leukaemia |
| 04/27/2011 | EP2313770A2 Multi-sample particle analyzer system and method for high throughput screening |
| 04/27/2011 | EP2313531A1 Gene expression profiling for identification, monitoring, and treatment of osteoarthritis |
| 04/27/2011 | EP2313530A2 A method of manufacturing a mixture of amplified double-stranded nucleic acids comprising unknown sequence |
| 04/27/2011 | EP2313529A2 Method for determining reduced predisposition to cancer based on genetic profile |
| 04/27/2011 | EP2313528A2 Methods for the cytological analysis of cervical cells |
| 04/27/2011 | EP2313527A2 Lateral flow nucleic acid detector |
| 04/27/2011 | EP2313526A1 Identifying cancers sensitive to treatment with inhibitors of notch signaling |
| 04/27/2011 | EP2313525A2 Genetic variants for breast cancer risk assessment |
| 04/27/2011 | EP2313524A2 Genetic variants as markers for use in urinary bladder cancer risk assessment, diagnosis, prognosis and treatment |
| 04/27/2011 | EP2313523A2 Genetic variants predictive of cancer risk in humans |